New York, April 18, 2024 - PRISM MarketView - Shares in biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) rose nearly 4.0% in intraday trading on Wednesday after the company announced it would expand its Scientific Advisory Board to include oncology expertise.
Dr. Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School of Medicine joins the board, along with Pradeep Tyagi, PhD, MBA, Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Dr. Hafron and Dr. Tyagi bring deep expertise in clinical and translational research in cancer treatment, with a focus on urologic oncology.
“I look forward to working with Dr. Hafron and Dr. Tyagi in the advancement of our discovery efforts in the treatment of non-muscle invasive bladder cancer (NMIBC), a disease that affects nearly one million Americans.”
Dr. Michael Chancellor, M.D., Chief Medical Officer of Lipella
Lipella is developing LP-50 (intravesical pembrolizumab) as a potential treatment for non-muscle invasive bladder cancer (NMIBC). LP-50 offers the potential for increasing efficacy while minimizing systemic toxicity. Lipella has generated preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI.
ABOUT LIPELLA PHARMACEUTICALS INC.
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, the company maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella recently completed an initial public offering in December 2022. For more information, visit www.lipella.com or LinkedIn for updates.
Lipella Pharmaceuticals (Nasdaq: LIPO) is featured on PRISM Emerging Pharma Index
About PRISM MarketView
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)